Free press releases distribution network?

Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Production Restructuring Pharmaceutical Companies to Propel Fine Chemicals Market in North America - Frost & Sullivan finds that the North American Fine Chemicals Market - Investment Analysis and Growth Opportunities earned revenue of $21.29 billion in 2005 and estimates them to reach $28.62 billion in 2011.
Production Restructuring Pharmaceutical Companies to Propel Fine Chemicals Market in North America

 

PRZOOM - /newswire/ - Palo Alto, CA, United States, 2006/03/16 - Frost & Sullivan finds that the North American Fine Chemicals Market - Investment Analysis and Growth Opportunities earned revenue of $21.29 billion in 2005 and estimates them to reach $28.62 billion in 2011..

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The increasing focus of pharmaceutical companies on research and development (R&D) as well as their reduced emphasis on captive manufacturing are driving the fine chemicals market in North America. Fine chemicals suppliers offer products at lower costs, reduce marketing time, as well as enable pharma companies to focus on their core competencies and employ beneficial reorganization processes.

Frost & Sullivan finds that the North American Fine Chemicals Market - Investment Analysis and Growth Opportunities earned revenue of $21.29 billion in 2005 and estimates them to reach $28.62 billion in 2011.

If you are interested in a virtual brochure, which provides financial executives, investment professionals, marketing directors, business development executives, and other industry participants an overview of the latest analysis of the North American Fine Chemicals Market - Investment Analysis and Growth Opportunities then send an e-mail to Trisha Bradley - Corporate Communications at trisha.bradley[.]frost.com with the following information: your full name, company name, title, telephone number, e-mail address, city, state, and country. We will send you the information via email upon receipt of the above information.

“The growing number of suppliers from Asia, which offer goods at lesser prices than their North American counterparts and are compliant with current good manufacturing practices (cGMP) as well as intellectual property rights (IPR), are increasingly catering to multinational pharma enterprises,” states Frost & Sullivan Research Analyst Shrikanth Srinivasan.

India, for instance, has over 70 cGMP-compliant factories – the second largest in the world after the United States – and the prices offered by manufacturers in India and China are 50.0 percent of those provided by companies in North America. This could be mainly due to the lower fixed, labor and maintenance costs prevalent in Asia that translates to 10.0 percent of the expenditure incurred by North American manufacturing plants.

In addition to the intense competition from Asian fine chemicals suppliers, the slump in the rate of new chemical entity (NCE) approvals curtail the profitability of fine chemicals companies.

“To stay competitive in this scenario, participants in the North American fine chemicals market are opting for restructuring, the outcome of which is likely to depend largely on production restructuring in pharmaceutical companies,” notes Srinivasan. “The quicker the measures taken by pharma companies, the greater will be the reduction of overcapacity in the fine chemicals markets.”

Encouragingly, the contract biopharma segment is set to witness strong growth as biopharmaceuticals are attracting greater venture capital (VC) funding. Also, the currently undervalued pure play pharmaceutical intermediaries and active pharmaceutical ingredients (API) businesses present the best opportunities for private equity participants to enter the market.

Overall, fine chemicals manufacturers supplying to North America must concentrate on niche technologies such as high potency active pharmaceutical ingredients (HPAPI) to gain ground in the long run. These units should emphasize maintaining confidentiality, building a top-notch reputation, as well as providing documentation and superior product quality to gain advantage over their Asian rivals.

North American Fine Chemicals Market - Investment Analysis and Growth Opportunities, a part of the Financial Benchmarking & Analysis in the Specialty Chemicals subscription and the Total Chemicals, Materials & Food subscription, provides an overview of the various industry segments, including pharmaceutical intermediates, active pharmaceutical ingredients, contract biopharma, and agrochemical intermediates. Analyst interviews are available to the press.

Frost & Sullivan's Business and Financial Services group serves clients around the world in all aspects of financial analysis, market research and monitoring, due diligence, idea generation, opportunity analysis, investment valuation and other proprietary research.

Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Production Restructuring Pharmaceutical Companies to Propel Fine Chemicals Market in North America

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Trisha Bradley 
210.247.3870 trisha.bradley[.]frost.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

PleurX™ Catheter System Receives FDA 510(k) Clearance for Specific Non-Malignant Recurrent Pleural Effusions
First Pulmonary Embolism Patients in Hong Kong Treated with the EKOS® System
Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Genentech’s Cancer Immunotherapy Tecentriq® (Atezolizumab) Priority Review in Additional Type of Advanced Bladder Cancer
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Myopic Choroidal Neovascularization
Sugar Element of Keratan Sulfate Halts the Progress of Emphysema Finds RIKEN
Exelixis and Ipsen Amend Exclusive Licensing Agreement for the Commercialization and Development of Cabozantinib to Include Canada
FDA Extends Review of Application for OCREVUS™ (Ocrelizumab)
MDxHealth Announces AceCGT Life Science Limited as the Exclusive Distributor for SelectMDx in Hong Kong and Macao China
Pulse Certified As A Level Four Multichannel Content Agency by Veeva Systems

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  NAKIVO, Inc.

Visit  1Click Games

Visit  Al Rowaad Advocates & Legal Consultants







 
  ©2017 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today